Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Reporting QC Out-of-Specification Results – V 2.0

Posted on By

Elixir Department: SOP for Reporting QC Out-of-Specification Results – V 2.0

Standard Operating Procedure for Reporting QC Out-of-Specification (OOS) Results in Elixir Testing

Department Elixir Department
SOP No. SOP/ELX/238/2025
Supersedes SOP/ELX/238/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To outline the procedure for identifying, documenting, investigating, and reporting Out-of-Specification (OOS) test results observed during the Quality Control analysis of elixir products, in compliance with cGMP and regulatory standards.

2. Scope

This SOP applies to all Quality Control (QC) testing activities including raw materials, in-process, finished product, and stability samples related to elixir formulations at any testing stage.

3. Responsibilities

  • QC Analyst:
    • Immediately notify any observed OOS result and document data accurately.
  • QC Supervisor:
    • Review test data and initiate a Phase I laboratory investigation.
  • QA Officer:
    • Initiate Phase II investigation if required and ensure regulatory compliance of the OOS report.
See also  Elixir Department: SOP for Conductivity Testing - V 2.0

4. Accountability

The Head of QC is accountable for ensuring timely and complete reporting of OOS events. The Head of QA is responsible for ensuring proper documentation and final disposition of affected materials.

5. Procedure

5.1 Identification of OOS

  1. An OOS result is any test result that falls outside the approved specification range or trend limits.
  2. The analyst must immediately:
    • Stop further testing on the batch
    • Notify the QC Supervisor
    • Record the result and conditions in the raw data sheet

5.2 Phase I: Laboratory Investigation

  1. QC Supervisor reviews the method, calculations, standards, reagents, and instrument conditions.
  2. Determine if the result is due to:
    • Analytical error
    • Instrument malfunction
    • Improper sample preparation
  3. Repeat the test only with QA approval if lab error is confirmed.
See also  Elixir Department: SOP for Handling Deviations During Manufacturing - V 2.0

5.3 Phase II: Full-Scale Investigation

  1. If no lab error is confirmed, QA initiates a Phase II investigation.
  2. Evaluate:
    • Manufacturing deviations
    • Equipment logs and calibration history
    • Batch manufacturing record (BMR)
  3. Prepare a formal OOS Investigation Report with CAPA (Corrective and Preventive Actions).

5.4 Decision and Disposition

  1. QA, in consultation with QA/QC and Production, makes a decision on the product status:
    • Release (if valid retest justifies original result)
    • Reject (if result confirmed)
    • Rework (if permitted)
  2. Update the Product Quality Review (PQR) with any confirmed OOS.

5.5 Documentation

  1. Maintain all data in the OOS Register (Annexure-1).
  2. Attach raw data, investigation checklist, and CAPA form.
  3. Final report must be signed by QA Head before closure.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • OOS: Out-of-Specification
  • CAPA: Corrective and Preventive Action
  • QC: Quality Control
  • QA: Quality Assurance
  • BMR: Batch Manufacturing Record
See also  Elixir Department: SOP for Storage of Raw Materials for Elixir Manufacturing - V 2.0

7. Documents

  1. OOS Register (Annexure-1)
  2. OOS Investigation Form
  3. CAPA Form

8. References

  • 21 CFR Part 211.192 – Production Record Review
  • MHRA OOS Guidelines
  • WHO Technical Report Series No. 996, Annex 2

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: OOS Register

Date Batch No. Test Parameter OOS Value Specification Disposition QA Review
11/04/2025 ELX-0425-054 Assay 88.2% 90.0% – 110.0% Rejected Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP Creation QA Head
11/04/2025 2.0 Updated with phase-wise investigation process GMP Enhancement QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Analytical Method Development: SOP for Verification of Compendial Methods – V 2.0
Next Post: Analytical Method Development: SOP for Preparation and Approval of Working Standards – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version